<DOC>
	<DOCNO>NCT00549185</DOCNO>
	<brief_summary>The primary objective determine maximum tolerate dose SAR3419 characterize dose limit toxicity ( y ) . Secondary objective determine anti-lymphoma activity , global safety PK profile .</brief_summary>
	<brief_title>Multi-dose-escalation Safety Pharmacokinetic Study SAR3419 Single Agent Relapsed/Refractory B-cell Non Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Histologically confirm CD19positive nonHodgkin 's Bcell lymphoma , relapse refractory standard treatment , curative option conventional therapy ECOG performance status 0 2 Burkitt 's lymphoma , Lymphoblastic lymphoma , Chronic lymphocytic leukemia ( Small lymphocytic lymphoma may include ) Chemotherapy radiation therapy investigational agent within 4 week prior enter study Previous radioimmunotherapy within 12 week Known intolerance infuse protein product maytansinoids Poor kidney , liver bone marrow function Any serious active disease comorbid condition , opinion principle investigator , interfere safety compliance study Pregnant breastfeed woman Patient reproductive potential without effective birth control methods The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>